​

Collegium Pharmaceutical (COLL) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Collegium Pharmaceutical Revenue Highlights

Latest Revenue (Y)

$631.45M

Latest Revenue (Q)

$159.30M

Main Segment (Y)

Belbuca

Collegium Pharmaceutical Revenue by Period

Collegium Pharmaceutical Revenue by Year

DateRevenueChange
2024-12-31$631.45M11.41%
2023-12-31$566.77M22.17%
2022-12-31$463.93M67.56%
2021-12-31$276.87M-10.69%
2020-12-31$310.02M4.49%
2019-12-31$296.70M5.81%
2018-12-31$280.41M884.73%
2017-12-31$28.48M1564.29%
2016-12-31$1.71M100.00%
2015-12-31-100.00%
2014-12-31-100.00%
2013-12-31--

Collegium Pharmaceutical generated $631.45M in revenue during NA 2024, up 11.41% compared to the previous quarter, and up 212.82% compared to the same period a year ago.

Collegium Pharmaceutical Revenue by Quarter

DateRevenueChange
2024-09-30$159.30M9.65%
2024-06-30$145.28M0.24%
2024-03-31$144.92M-3.22%
2023-12-31$149.75M9.54%
2023-09-30$136.71M0.86%
2023-06-30$135.55M-6.37%
2023-03-31$144.77M11.69%
2022-12-31$129.62M2.05%
2022-09-30$127.01M2.80%
2022-06-30$123.55M47.52%
2022-03-31$83.75M206.09%
2021-12-31$27.36M-65.30%
2021-09-30$78.84M-4.94%
2021-06-30$82.94M-5.45%
2021-03-31$87.72M15.01%
2020-12-31$76.27M-3.67%
2020-09-30$79.18M1.43%
2020-06-30$78.06M2.02%
2020-03-31$76.51M3.11%
2019-12-31$74.20M1.73%
2019-09-30$72.94M-2.80%
2019-06-30$75.04M0.70%
2019-03-31$74.52M1.48%
2018-12-31$73.43M4.63%
2018-09-30$70.18M-3.95%
2018-06-30$73.06M14.61%
2018-03-31$63.75M490.60%
2017-12-31$10.79M-9.67%
2017-09-30$11.95M235.67%
2017-06-30$3.56M63.90%
2017-03-31$2.17M66.69%
2016-12-31$1.30M219.36%
2016-09-30$408.00K100.00%
2016-06-30-100.00%
2016-03-31-100.00%
2015-12-31-100.00%
2015-09-30-100.00%
2015-06-30-100.00%
2015-03-31-100.00%
2014-12-31-100.00%
2014-09-30-100.00%
2014-06-30-100.00%
2014-03-31--

Collegium Pharmaceutical generated $159.30M in revenue during Q3 2024, up 9.65% compared to the previous quarter, and up 117.53% compared to the same period a year ago.

Collegium Pharmaceutical Revenue Breakdown

Collegium Pharmaceutical Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24Dec 23Dec 22Dec 21Dec 20
Belbuca$211.27M$182.09M$126.46M--
Nucynta ER$75.77M$82.65M$72.42M$70.94M-
Nucynta IR$100.74M$108.15M$112.06M$102.22M-
Symproic$15.10M$16.50M$12.27M--
Xtampza ER$191.33M$177.37M$138.80M$103.71M-
Other--$1.93M--
Nucynta Products---$173.16M-
Xtampza----$127.98M
Nucynta Er----$65.71M
Nucynta Ir----$116.32M
Nucynta----$182.03M

Collegium Pharmaceutical's latest annual revenue breakdown by segment (product or service), as of Dec 24: Belbuca (35.55%), Xtampza ER (32.20%), Nucynta IR (16.95%), Nucynta ER (12.75%), and Symproic (2.54%).

Quarterly Revenue by Product

Product/ServiceDec 24Sep 24Mar 24Dec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Sep 19Jun 19
Xtampza ER$96.03M$49.49M$45.81M$88.26M$41.24M$47.87M$35.24M$38.86M$33.19M$31.52M----------
Belbuca$107.41M$53.20M$50.66M$94.75M$43.14M$44.21M$42.05M$38.80M$42.30M$3.31M----------
Nucynta ER$36.81M$19.77M$19.19M$42.35M$19.17M$21.14M$18.95M$17.13M$17.08M$19.26M$8.73M---------
Nucynta IR$49.42M$25.36M$25.96M$52.09M$28.16M$27.90M$28.89M$27.27M$26.55M$29.34M$13.37M---------
Symproic$8.29M$3.52M$3.30M$9.01M$3.84M$3.65M$4.53M$3.58M$3.86M$300.00K----------
Other------$320.00K$1.15M$458.00K-----------
Elyxyb-------$218.00K$109.00K$25.00K----------
Nucynta-----------$48.83M$49.92M$52.31M$45.48M$47.05M$44.50M$45.00M$46.46M$49.02M
Nucynta Er-----------$19.74M$20.68M$21.79M$16.20M$17.05M$15.43M$17.03M--
Nucynta Ir-----------$29.09M$29.24M$30.53M$29.27M$30.00M$29.07M$27.97M--
Xtampza-----------$30.02M$33.02M$35.41M$30.79M$32.13M$33.56M$31.51M$26.48M$26.02M

Collegium Pharmaceutical's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Belbuca (36.05%), Xtampza ER (32.23%), Nucynta IR (16.59%), Nucynta ER (12.35%), and Symproic (2.78%).

Collegium Pharmaceutical Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
RDYDr. Reddy's Laboratories$279.16B-
ALKSAlkermes$1.56B$378.14M
PBHPrestige Consumer Healthcare$1.13B$290.32M
PAHCPhibro Animal Health$977.89M$309.26M
AMPHAmphastar Pharmaceuticals$712.81M$188.82M
PCRXPacira BioSciences$700.97M$168.57M
ITCIIntra-Cellular Therapies$680.85M$175.38M
COLLCollegium Pharmaceutical$631.45M$159.30M
ANIPANI Pharmaceuticals$614.38M$148.33M
PROCProcaps Group$409.92M$118.41M
EOLSEvolus$264.31M$60.16M
RGCRegencell Bioscience--

COLL Revenue FAQ

What is Collegium Pharmaceutical’s yearly revenue?

Collegium Pharmaceutical's yearly revenue for 2024 was $631.45M, representing an increase of 11.41% compared to 2023. The company's yearly revenue for 2023 was $566.77M, representing an increase of 22.17% compared to 2022. COLL's yearly revenue for 2022 was $463.93M, representing an increase of 67.56% compared to 2021.

What is Collegium Pharmaceutical’s quarterly revenue?

Collegium Pharmaceutical's quarterly revenue for Q3 2024 was $159.3M, a 9.65% increase from the previous quarter (Q2 2024), and a 16.53% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $145.28M, a 0.24% increase from the previous quarter (Q1 2024), and a 7.18% increase year-over-year (Q2 2023). COLL's quarterly revenue for Q1 2024 was $144.92M, a -3.22% decrease from the previous quarter (Q4 2023), and a 0.11% increase year-over-year (Q1 2023).

What is Collegium Pharmaceutical’s revenue growth rate?

Collegium Pharmaceutical's revenue growth rate for the last 3 years (2022-2024) was 36.11%, and for the last 5 years (2020-2024) was 103.68%.

What are Collegium Pharmaceutical’s revenue streams?

Collegium Pharmaceutical's revenue streams in c 24 are Belbuca, Nucynta ER, Nucynta IR, Symproic, and Xtampza ER. Belbuca generated $211.27M in revenue, accounting 35.55% of the company's total revenue, up 16.02% year-over-year. Nucynta ER generated $75.77M in revenue, accounting 12.75% of the company's total revenue, down -8.33% year-over-year. Nucynta IR generated $100.74M in revenue, accounting 16.95% of the company's total revenue, down -6.85% year-over-year. Symproic generated $15.1M in revenue, accounting 2.54% of the company's total revenue, down -8.43% year-over-year. Xtampza ER generated $191.33M in revenue, accounting 32.20% of the company's total revenue, up 7.87% year-over-year.

What is Collegium Pharmaceutical’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Collegium Pharmaceutical was Belbuca. This segment made a revenue of $211.27M, representing 35.55% of the company's total revenue.